Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 19Neoplasm Metastasis 13Melanoma 12Nasopharyngeal Carcinoma 10Carcinoma, Non-Small-Cell Lung 10Stomach Neoplasms 8Rectal Neoplasms 8Pancreatic Neoplasms 8Colorectal Neoplasms 8Squamous Cell Carcinoma of Head and Neck 6Neoplasms 6Locally Advanced Rectal Cancer 6Carcinoma, Renal Cell 6Uterine Cervical Neoplasms 4Recurrence 4Lymphoma, Extranodal NK-T-Cell 4Triple Negative Breast Neoplasms 3Sarcoma 3Nasopharyngeal Neoplasms 3Glioblastoma 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Cholangiocarcinoma 3Thyroid Neoplasms 2Solid Tumor 2Prostatic Neoplasms 2Lymphoma 2Lung Neoplasms 2Kidney Neoplasms 2Gastrointestinal Stromal Tumors 2

Interventions

spartalizumab 1Immunotherapy 1Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Objective Response Rate × spartalizumab × Clear all
NCT05760196 2023-03-08

Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors

Renmin Hospital of Wuhan University

Phase 2 Unknown
56 enrolled

Objective Response Rate

Data powered by HemOnc (CC BY 4.0) Colophon âš¡